We wrote late last year about the recent upswing in big pharma M&A activity, due in part to a patent cliff that is forcing major players to supplement their drug portfolios with late stage candidates. Key indications of focus include cardiometabolic diseases. Right on cue, this year started with a bang.
Eli Lilly’s agreement to acquire Ventyx Biosciences (Nasdaq: VTYX) for about $1.2 billion represents the kind of deal that gets biotech and pharma investors sitting up straighter in their chairs. On the surface, it looks rich: Ventyx had a bruising trading history after earlier clinical setbacks and its stock spent much of the last year priced like a “broken” small cap rather than a hot strategic asset, offering a 62% premium to the 30‑day volume-weighted average price before the deal was announced. But Lilly isn’t paying for where the stock has been. It’s paying for where the underlying science can go.
What Lilly is really buying is a portfolio of NLRP3 inflammasome inhibitors. These are oral, small‑molecule drugs that sit right at the crossroads of inflammation, cardiometabolic disease, and neuroinflammation. NLRP3 is a master switch for IL‑1–driven inflammation, and the same pathway underpins several indications including recurrent pericarditis, Parkinson’s disease, and residual cardiovascular risk. Ventyx offered a few shots on goal across large and niche indications. Lilly, flush with cash from its obesity and diabetes franchises, essentially decided it would rather write a $1.2 billion check than spend five to ten years re‑creating that portfolio internally.
From a pharma strategy perspective, the deal fits a clear pattern. Big buyers want:
- A mechanism that matters across multiple diseases (NLRP3/IL‑1 fits).
- Oral, chronic therapies that can plug into existing commercial infrastructure.
- A portfolio or platform, not just a one‑off drug.
They’re increasingly willing to overlook ugly stock charts if the mechanistic story is compelling and the programs are far enough along to de‑risk the science. Ventyx ticked those boxes, and Lilly moved.
Another Candidate for the Trend, A Comparable Player in the Space
Now take a look at Cardiol Therapeutics (Nasdaq: CRDL) (TSX: CRDL). Cardiol works in a similar thematic lane: inflammation‑driven cardiac disease, clinically meaningful structural endpoints, and a pipeline that spans a rare orphan indication and a massive mainstream market.
Cardiol’s lead program, CardiolRx, is in a fully funded pivotal Phase III trial in recurrent pericarditis called MAVERIC. The company already ran a successful Phase II study (MAvERIC‑Pilot), showing that CardiolRx rapidly reduced chest pain and inflammation and cut recurrence rates in this debilitating condition. The FDA has granted Orphan Drug Designation here, and the Phase III design focuses on patients who have a high risk of relapse. But the designation also covers CardiolRx use earlier in the recurrent pericarditis treatment paradigm—before patients are exposed to prolonged corticosteroid use or immunosuppressive biologics such as IL-1 inhibitors.
That alone puts Cardiol in rarefied company. The inflammasome is a validated target as IL‑1 blockers have shown that shutting down the inflammatory mediators generated from activation of the inflammasome pathway can transform patient outcomes. However, the category remains wide open for an oral, chronic therapy that could be easier to use, more affordable, or better tolerated than biologic injectables. It’s the kind of opportunity where a positive Phase III readout can quickly turn into a registrational filing and, in the right hands, a durable orphan franchise.
Multiple Indications
But the story doesn’t stop at pericarditis. In late 2025, Cardiol released full results from its Phase II ARCHER trial evaluating CardiolRx in acute myocarditis. The readout included relevant data showing an impact on the heart that was under appreciated by the market. Over just 12 weeks, patients on CardiolRx experienced a statistically significant reduction in left ventricular (LV) mass, along with improvements in cardiac MRI markers of edema and remodeling. In plainer language: the drug helped an inflamed heart start to look and behave more normal again.
Source: Cardiol Therapeutics Investor Presentation – December 2025
Why does that matter? Because LV mass is not a cosmetic metric. It’s a well‑established predictor of bad outcomes in multiple cardiac conditions, including heart failure. Drugs that reduce LV mass and reverse maladaptive remodeling, like some SGLT2 inhibitors and renin‑angiotensin system blockers, have historically been associated with lower hospitalization and mortality risk. Cardiol now has human data suggesting its active ingredient can move that structural dial in an inflammatory cardiomyopathy setting.
That feeds directly into Cardiol’s third pillar: CRD‑38, a subcutaneous (injectable) formulation of the same drug substance being developed for heart failure. In preclinical models, subcutaneous cannabidiol improved ejection fraction, reduced hypertrophy and fibrosis, and lowered inflammatory and cell‑death markers, essentially hitting the same mechanisms that drive heart failure progression from multiple angles.
Management has been explicit that the ARCHER LV mass data provide clinical validation for pushing CRD‑38 into IND‑enabling studies for heart failure, a vastly larger opportunity than either pericarditis or myocarditis. In fact, Cardiol’s most recent financing of $11.4 million accelerates those IND-enabling studies and the company has been in discussions with larger companies about collaborating on the clinical development of the drug candidate.
Ventyx Comparison
If you line this up next to Ventyx, some parallels emerge:
- Both companies are targeting inflammation at the heart of serious cardiovascular and pericardial diseases – through the NLRP3 inflammasome .
- Both see recurrent pericarditis as a key opportunity where injectable IL‑1 blockers have demonstrated the pathway but left room for oral or more convenient options.
- Both have ambitions that extend into other larger indications where residual inflammation and structural remodeling drive risk: cardiometabolic disease for Ventyx; myocarditis, cardiomyopathies and heart failure for Cardiol.
| Aspect | Ventyx Biosciences (Acquired by Lilly) | Cardiol Therapeutics |
| Core Mechanism | NLRP3 inflammasome inhibitors | Cannabidiol-based anti-inflammatories |
| Lead Indications | Recurrent pericarditis, Parkinson’s, cardiometabolic | Recurrent pericarditis, acute myocarditis, heart failure |
| Development Stage | Pre-Phase III portfolio | Phase III ongoing in pericarditis; Phase II data in myocarditis; Preclinical for heart failure |
| Delivery Method | Oral small-molecule | Small-molecule oral (CardiolRx) and subcutaneous (CRD-38) |
| Market Perception | Undervalued post-setbacks; Acquired at premium | Independent with funded trials; Potential partnership discussions |
| Strategic Appeal | Platform with multiple shots on goal | Validated data in structural endpoints; Orphan drug designation in pericarditis |
The big difference is timing and perception. Ventyx sold itself as a platform play before any single program reached Phase III. Lilly paid for the portfolio optionality and depth, despite the market having largely written off the stock after earlier failures. Cardiol, by contrast, is still independent, has one drug in a pivotal Phase III orphan trial for recurrent pericarditis, human Phase II proof‑of‑concept in myocarditis (LV‑mass data) with the same drug, and a next‑gen heart failure candidate completing IND-enabling studies.
That is exactly the kind of package that makes larger companies start running spreadsheets. Ventyx shows how far a big acquirer will go when it believes a drug targeting a mechanism like NLRP3 activation can underpin a new franchise. Cardiol doesn’t have quite the same pipeline breadth as Ventyx, but it does have something arguably more concrete: later stage human data in the heart and a fully funded Phase III in a well‑defined orphan population.
The prospects get exponentially stronger should the Phase III trial succeed. A positive MAVERIC readout in recurrent pericarditis would give Cardiol:
- A de‑risked, late‑stage asset in an orphan indication with clear regulatory precedent and commercial prospects.
- A clinically validated inflammation‑modulating mechanism in structural heart disease.
- A compelling story for why the same drug substance (or its subcutaneous cousin) should be taken seriously in heart failure.
The Upshot
For investors, the takeaway is not that Cardiol is “the next Ventyx” in some simplistic sense. The capital structures, deal dynamics, and exact mechanisms are different. But the Lilly–Ventyx deal is a useful lens. It shows that Big Pharma is willing to pay big money for inflammation‑based approaches to pericarditis and cardiovascular disease. Cardiol operates in the same space with a Phase III pericarditis trial in progress, myocarditis LV‑mass data in hand, and a heart‑failure candidate queued up. The company could become a very interesting conversation piece for larger players prior to or following its next clinical and development milestones. As of early 2026, with ongoing trials and recent financing, Cardiol’s market cap remains modest compared to its potential, making it a watchlist candidate for those betting on anti-inflammatory breakthroughs in cardiology.
